Eric Benevich - Neurocrine Biosciences Chief Commercial Officer
| NBIX Stock | USD 111.92 1.85 1.68% |
Executive
Mr. Eric S. Benevich serves as Chief Commercial Officer of the Company. He was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel, Epogen and Prilosec since 2015.
| Age | 60 |
| Tenure | 10 years |
| Address | 12780 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Eric Benevich Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Benevich against Neurocrine Biosciences stock is an integral part of due diligence when investing in Neurocrine Biosciences. Eric Benevich insider activity provides valuable insight into whether Neurocrine Biosciences is net buyers or sellers over its current business cycle. Note, Neurocrine Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neurocrine Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Benevich over three weeks ago Disposition of 1098 shares by Eric Benevich of Neurocrine Biosciences at 116.7421 subject to Rule 16b-3 |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.1046 % which means that it generated a profit of $0.1046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1416 %, meaning that it created $0.1416 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2025. Return On Capital Employed is likely to rise to 0.19 in 2025. At this time, Neurocrine Biosciences' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.67 in 2025, whereas Intangibles To Total Assets are likely to drop 0.01 in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Todd MBA | Supernus Pharmaceuticals | N/A | |
| Shawn Cross | Pacira BioSciences, | 57 | |
| Peter Norman | Alkermes Plc | N/A | |
| Volker Braun | Evotec SE ADR | N/A | |
| MBA MPH | Amphastar P | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| MBA MD | Supernus Pharmaceuticals | 63 | |
| Dong Yu | Dynavax Technologies | N/A | |
| Ronald Silver | Ironwood Pharmaceuticals | 42 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| MD MBA | Supernus Pharmaceuticals | 64 | |
| DO Ellis | Pacira BioSciences, | 53 | |
| Karen Esq | Intracellular Th | 62 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Blair Jackson | Alkermes Plc | 52 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Aurelie Dalbiez | Evotec SE ADR | 48 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Kristen JD | Pacira BioSciences, | 51 | |
Management Performance
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Cooke, Chief People Officer | ||
| Matthew Abernethy, Chief Officer | ||
| Eric Benevich, Chief Commercial Officer | ||
| Darin Lippoldt, Chief Legal Officer | ||
| Jude Onyia, Chief Officer | ||
| Dimitri Grigoriadis, Chief Research Officer | ||
| Kyle Gano, Chief Business Development Officer | ||
| Darin Esq, Chief Secretary | ||
| Jane Sorensen, Investor Relations Officer | ||
| Eiry MD, Chief Officer | ||
| David Boyer, Chief Officer | ||
| BA MD, CoFounder Neurocrine | ||
| Kevin Gorman, CEO and President and Director | ||
| Matthew CPA, Chief Officer | ||
| Ingrid Delaet, Chief Officer | ||
| Christopher OBrien, Exclusive Consultant | ||
| Wylie Vale, CoFounder |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 10.35 B | ||||
| Shares Outstanding | 99.7 M | ||||
| Shares Owned By Insiders | 1.02 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 3.04 M | ||||
| Price To Earning | 202.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.